InvestorsHub Logo
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Wednesday, 11/14/2018 8:25:55 AM

Wednesday, November 14, 2018 8:25:55 AM

Post# of 867
KEYNOTE-181 in second-line esophageal cancer hits primary OS endpoint in PDL1+ subgroup, misses in overall trial (ITT population):

https://www.businesswire.com/news/home/20181114005229/en/Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Significantly-Improved-Survival-OS

The trial tested Ketruda monotherapy vs standard chemo. No HR figures have been disclosed yet.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRK News